Oil Gains Amid Optimism Over U.S.-China Trade Talks
0000 GMT — Oil edges higher in the early Asian session, buoyed by optimism over U.S.-China trade talks that could mitigate risks of tariffs hurting oil demand. President Trump's negotiators sit down with their Chinese counterparts in London later today. Also, supply-side risks are providing extra short- to medium-term support, such as recent wildfires in Canada that threaten production, Saxo Bank's head of Commodity Strategy Ole Hansen says. Front-month WTI crude oil futures are up 0.2% at $64.69/bbl; front-month Brent crude oil futures are 0.2% higher at $66.56/bbl. (ronnie.harui@wsj.com)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
15 minutes ago
- Wall Street Journal
Heard on the Street Recap: Musk's xAI Debt Deal
U.S. hiring slowed mildly. The economy added 139,000 jobs in May, down from 147,000 in April, but above the 125,000 roles economists expected. The unemployment rate was steady at 4.2%.
Yahoo
22 minutes ago
- Yahoo
First Hydrogen Announces Strategic Collaboration with Renewable Thermal Laboratory at the University of Alberta to Advance Nuclear SMR Technology
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - First Hydrogen Corp. (TSXV: FHYD) (OTC Pink: FHYDF) (FSE: FIT) ("FIRST HYDROGEN" or the "Company") is pleased to announce a strategic collaboration with Professor Muhammad Taha Manzoor from the University of Alberta aimed at advancing Small Modular Nuclear Reactor (SMR) technology, specifically focusing on fuel reactor materials and reactor design optimization taking into consideration the growth of artificial intelligence (AI) data centres as they consume up 10 times more power than normal data centres (Ithy - Comparative Power Consumption of AI Servers and Normal Servers in Data Centers). The project will take into consideration the surge in AI data centres and energy needs worldwide. The project will be led by Dr. Manzoor, an expert in molten salt thermal-hydraulics and lead at the Renewable Thermal Laboratory that has projects ranging from thermal energy storage to small modular nuclear reactors. Molten salt, as a coolant and nuclear fuel, is the future of nuclear energy due its: Safety - if the salt overheats, it naturally expands and makes the fission reaction less effective which will shut down the reactor. Efficiency - molten salt reactor cores can change its power level to match heat removal for electricity production. Flexibility - can be used with uranium, plutonium and thoriumSource: Idaho National Laboratoryhttps:// This collaboration aligns with First Hydrogen's mission to pioneer sustainable, efficient, and safe energy solutions, leveraging nuclear technology to produce green hydrogen and support global decarbonization objectives. First Hydrogen seeks to integrate advanced nuclear technology with green hydrogen production. SMRs, known for their compact design, scalability, and ability to provide a continuous, weather-independent power supply, are the cornerstone of this initiative. By leveraging SMRs, First Hydrogen ensures a stable, cost-effective, and efficient process for producing green hydrogen, addressing the growing demand for clean energy solutions worldwide. The International Energy Agency reported artificial intelligence from data centres will drive electricity demand. By 2030, electricity demand from data centres worldwide is expected to more than double to 945 terawatt hours, more than the entire electricity consumption of Japan today. ( According to McKinsey and Company, the AI book is driving significant investment in data centres. Their research indications that approximately $5.2 trillion, in capital expenditures, will be required worldwide by 2030 to meet the increasing demand for computing power. ( Dr. Manzoor commented, "We are excited to collaborate with First Hydrogen on molten salt small modular nuclear reactor research. The signing of this letter of support marks an important first step in what promises to be a series of significant milestones in advancing SMR technology in Canada. This industry-led project will provide students with valuable hands-on experience and help train the next generation of engineers and scientists who will contribute to the growth and diversification of Canada's energy sector." Balraj Mann, CEO of First Hydrogen, stated, "We are excited to collaborate with the University of Alberta, leveraging their expertise in nuclear research to significantly advance nuclear fuels for SMRs. This collaboration underscores our commitment to driving innovation in clean energy solutions that will play a critical role in transitioning toward a zero-emission future." About First Nuclear Corp. ( Hydrogen Corp. is committed to developing and commercializing advanced clean energy solutions, including green hydrogen produced by state-of-the-art Small Modular Reactors. The Company aims to provide scalable, sustainable, and economically viable alternatives to meet global climate goals and enhance energy security. About First Hydrogen Corp. ( First Hydrogen Corp. is a Vancouver, Montreal, Germany and London UK-based company focused on zero-emission vehicles, green hydrogen production and distribution. The Company has designed and built two hydrogen- fuel-cell-powered light commercial vehicles ("FCEV"). The FCEV are road-legal in the United Kingdom (excluding Northern Ireland) with 6,000 km of testing completed and have achieved a range of 630+ kilometres on a single refueling. The vehicles have successfully been trialled in real-world conditions with fleet operators in the United Kingdom. On behalf of the Board of Directors of FIRST HYDROGEN CORP."Balraj Mann"Chairman & Chief Executive Officer Contact:Balraj Mann First Hydrogen Corp.604-601-2018investors@ Cautionary Note Regarding Forward-Looking Statements This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of First Hydrogen, and includes statements about, among other things, future developments and the future operations, strengths and strategies of First Hydrogen. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results. The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for First Hydrogen's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions. The forward-looking information contained in this news release represents the expectations of First Hydrogen as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. First Hydrogen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICE PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. patent application covering one of its next-generation antibody-drug conjugate (ADC) technologies. The allowance of U.S. patent application no. 18/351,291 ('291) includes valuable composition-of-matter claims broadly covering therapeutically active ADCs - not limited to individual diseases or therapeutic targets - as well as claims covering the use of ADCs for treating or diagnosing diseases such as cancer. Defence's Accum®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs. Upon grant, the '291 patent application will provide the Company with potential market exclusivity until 2043 for its proprietary second-generation Accum®-based ADCs, which include antibodies conjugated to innovative new constructs featuring a bile acid conjugated to a nuclear localization signal (NLS) derived from the ribosomal protein eS17 (RPS17). This milestone builds on Defence's established patent portfolio for its foundational Accum® technology, which includes granted patents in the United States (US 11,352,437), Japan (JP 7,126,956), Australia (AU 2017233725), and Israel (IL 261765), with applications currently pending in Canada and Europe. "Second-generation Accum®-based ADCs represent a significant advancement in both oncotherapy and targeted drug delivery," said Sébastien Plouffe, CEO and Founder of Defence Therapeutics. "This recent allowance underscores the innovation and versatility embedded in our ADC platform technology and reflects our commitment to developing novel, effective cancer treatments that push the boundaries of current ADC technologies." This newly allowed U.S. patent application is poised to become the eighth granted U.S. patent in Defence's expanding portfolio, which now comprises seven published patent families. About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer. For further information:Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
